CRIS Current Research Information System

PAPAYANNIDIS, CRISTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 22.358
NA - Nord America 20.327
EU - Europa 15.523
AF - Africa 1.335
SA - Sud America 1.218
OC - Oceania 33
Continente sconosciuto - Info sul continente non disponibili 17
Totale 60.811
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 19.969
VN - Vietnam 6.279
SG - Singapore 5.537
CN - Cina 5.478
GB - Regno Unito 3.986
IT - Italia 2.624
SE - Svezia 2.223
DE - Germania 1.832
HK - Hong Kong 1.396
IN - India 1.016
FR - Francia 973
BR - Brasile 869
RU - Federazione Russa 737
NL - Olanda 636
KR - Corea 533
IE - Irlanda 523
BD - Bangladesh 472
JP - Giappone 424
ZA - Sudafrica 384
FI - Finlandia 344
UA - Ucraina 317
TG - Togo 289
EE - Estonia 270
CA - Canada 226
CI - Costa d'Avorio 223
CH - Svizzera 207
GR - Grecia 181
NG - Nigeria 172
JO - Giordania 161
BG - Bulgaria 159
AR - Argentina 158
PH - Filippine 146
SC - Seychelles 130
IR - Iran 112
ID - Indonesia 106
IQ - Iraq 104
BE - Belgio 98
TR - Turchia 96
TH - Thailandia 94
PL - Polonia 89
AT - Austria 77
MX - Messico 73
ES - Italia 72
TW - Taiwan 64
PK - Pakistan 54
UZ - Uzbekistan 54
EC - Ecuador 43
SA - Arabia Saudita 38
MY - Malesia 35
LB - Libano 29
VE - Venezuela 29
AU - Australia 27
CL - Cile 27
HR - Croazia 26
PY - Paraguay 26
EG - Egitto 25
CO - Colombia 24
TN - Tunisia 22
CZ - Repubblica Ceca 20
MA - Marocco 20
PE - Perù 20
LT - Lituania 19
RO - Romania 18
AE - Emirati Arabi Uniti 15
KE - Kenya 15
DZ - Algeria 14
KZ - Kazakistan 14
EU - Europa 12
IL - Israele 12
RS - Serbia 12
ET - Etiopia 11
NP - Nepal 11
OM - Oman 11
PT - Portogallo 11
UY - Uruguay 11
AZ - Azerbaigian 10
JM - Giamaica 9
MK - Macedonia 9
SK - Slovacchia (Repubblica Slovacca) 9
TM - Turkmenistan 9
TT - Trinidad e Tobago 9
QA - Qatar 8
AL - Albania 7
HN - Honduras 7
KG - Kirghizistan 7
MU - Mauritius 7
BA - Bosnia-Erzegovina 6
CR - Costa Rica 6
GY - Guiana 6
NO - Norvegia 6
NZ - Nuova Zelanda 6
PS - Palestinian Territory 6
BY - Bielorussia 5
DK - Danimarca 5
LV - Lettonia 5
PA - Panama 5
BB - Barbados 4
CY - Cipro 4
GH - Ghana 4
HU - Ungheria 4
Totale 60.727
Salva come PNG Salva come JPEG
Città #
Singapore 3.860
Southend 3.646
Ashburn 2.157
Chandler 1.626
Fairfield 1.483
San Jose 1.372
Dong Ket 1.344
Hong Kong 1.315
Ho Chi Minh City 1.196
Hanoi 1.014
Hefei 967
Houston 902
Beijing 836
Wilmington 794
Woodbridge 737
Santa Clara 717
Ann Arbor 709
Seattle 688
Princeton 654
Boardman 529
Dublin 518
Cambridge 514
Seoul 430
Bologna 423
New York 372
Lauterbourg 355
Nanjing 323
Los Angeles 322
Tokyo 322
Westminster 322
Lomé 289
Padova 285
Helsinki 266
Dallas 264
Medford 231
Abidjan 223
Milan 214
Bern 167
Frankfurt am Main 167
São Paulo 166
Buffalo 165
Haiphong 164
Shenyang 159
Amman 156
Sofia 153
Jinan 149
Da Nang 146
Berlin 143
Saint Petersburg 143
Munich 141
Redondo Beach 135
Council Bluffs 129
Redmond 126
Turin 125
Hebei 120
Nanchang 115
Abeokuta 111
Guangzhou 111
Bremen 105
Changsha 104
Shanghai 104
San Diego 101
Bengaluru 95
Florence 95
Rome 95
Brussels 93
Redwood City 91
Tianjin 84
Zhengzhou 78
Falls Church 77
Jacksonville 74
Jiaxing 71
Toronto 71
Johannesburg 68
Amsterdam 65
Hải Dương 64
Biên Hòa 63
Hangzhou 62
Phoenix 61
Orem 60
Chicago 57
Norwalk 57
Nuremberg 57
London 56
Baghdad 54
Jakarta 53
Falkenstein 51
Warsaw 50
Vienna 47
Can Tho 46
Montreal 45
Hyderabad 44
Paris 44
Ningbo 43
Turku 43
Athens 42
Brooklyn 42
Haikou 42
Mountain View 40
Taiyuan 40
Totale 37.944
Salva come PNG Salva come JPEG
Nome #
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted 662
Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery 390
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 355
A POLYMORPHISM IN THE CHROMOSOME 9P21 ANRIL LOCUS IS ASSOCIATED TO PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA SUSCEPTIBILITY 349
B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. 345
A NEW SUBSET OF ADULT B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENT WITH PREDNISONE-INDUCED MONOCYTIC DIFFERENTIATION? 337
Adult "Triple Negative" ACUTE Lymphoblastic Leukemia Genome Wide Characterization 324
A HIGH SENSITIVE NANOFLUIDIC ARRAY IMPROVES THE DETECTION OF RARE COPIES OF BCR-ABL1 TRANSCRIPT IN PATIENTS WITH PHILADELPHIA POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 316
Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia 315
A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia 305
Chromothripsis in acute myeloid leukemia: Biological features and impact on survival 305
A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium 295
Aggressive Aneuploid Acute Myeloid Leukemia Is Dependent on Alterations of P53, Gain of APC and PLK1 and Loss of RAD50 287
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia 283
EFFICACY, FEASIBILITY AND SAFETY OF NELARABINE SAVAGE THERAPY IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 275
Co-occurrence of alterations in the DNA damage repair genes synergize with uncontrolled proliferation and associate with very-poor prognosis in acute myeloid leukemia patients 273
Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient. 267
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience 267
Alterations in phosphatidylinositol 3-phosphate (PI3P) pathway and cAMP pathway confirm poor prognosis and reduced overall survival (OS) in a series of 209 acute myeloid leukemia patients 260
CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. 256
The alteration in key regulator genes of autophagy is mainstream mechanism of therapy resistance and impact prognosis of acute myelogenous leukemia (AML): results from diagnosis genomic analysis on 148 consecutive patients treated with intensive chemotherapy and long-term survival follow-up 256
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia 254
Prolonged low-dose azacitidine schedule in high-risk MDS patients: Hematologic and molecular response 254
Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience 254
Alterations of BRCA1 and PALB2 Define a Novel Class of Complex-Karyotype AML with a Very Bad Prognosis 250
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 249
A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia 244
Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis 244
Susceptibility to Philadelphia-Positive acute Lymphoblastic Leukemia (ALL) Is Associated with a Germline Polymorphism In the ANRIL (CDKN2BAS) Locus. 244
Epigenetically induced ectopic expression of uncx impairs the proliferation and differentiation of myeloid cells 241
CLINICAL OUTCOME OF T-ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (T-ALL/TLBL): THE BOLOGNA EXPERIENCE 239
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia 237
Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia 237
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations 235
Optimized pipeline of MuTect and GATK tools to improve the detection of somatic single nucleotide polymorphisms in whole-exome sequencing data 235
Novel and rare fusion transcripts involving transcription factors and tumor suppressor genes in acute myeloid leukemia 235
Identification of A Pharmacogenomic Profile Associated with High Sensitivity and Low Toxicity to a Combination of Gemtuzumab Ozogamicin Plus Fludarabine, Cytarabine, Idarubicin Regimen In CD33-Positive Acute Myeloid Leukemia (AML) Patients 234
A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma 232
Chromothripsis in AML patients: A new mechanism of cancer initiation and progression 232
Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia 232
Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Patients with Coronary Artery Disease and in Centenarians. Further Clues Linking Chip with Cardiovascular Risk 230
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 230
A cell cycle-related genomic and transcriptomic signature distinguish aneuploid and euploid acute myeloid leukemia 229
AZACITIDINE IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF LONG-RESPONDER PATIENTS 228
Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) patient with breast infiltration 228
WHOLE TRANSCRIPTOME DEEP-SEQUENCING IDENTIFIES NOVEL POINT MUTATIONS, GENE EXPRESSION AND ALTERNATIVE SPLICING PROFILES IN BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA 227
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: A new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients 227
ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112 227
Does Cytokine-Release Syndrome Induced by CAR T-Cell Treatment Have an Impact on the Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in Patients with Hematological Malignancies? Findings from an Observational Case-Control Study 225
LOSS OF THE TUMOR SUPPRESSOR GENE CDKN2A/ARF BY GENOMIC DELETIONS IS A FREQUENT EVENT IN ADULT BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS AND CONTRIBUTES TO DISEASE PROGRESSION 223
A case report of acute myeloid leukemia and neurofibromatosis 1 223
Flai (fludarabine, cytarabine, idarubicin) plus low-dose gemtuzumab ozogamicin as induction therapy in cd33-positive aml: Final results and long term outcome of a phase ii multicenter clinical trial 223
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 223
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 222
Larger size of donor alloreactive NK cell repertoire correlates with better response to NK cell immunotherapy in elderly acute myeloid leukemia patients 220
AZACITIDINE FOR HIGH RISK MYELODYSPLASTIC SYNDROMES. RETROSPECTIVE EVALUATION OF TWO DIFFERENT DOSING SCHEDULES 219
Use of a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript In Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (ALL). 219
The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) 219
Safety Run-In and Part 1 of GIMEMA AML1718: Venetoclax Combined with FLAI as Induction Treatment in Non-Low-Risk AML 218
AZACITIDINE IN HIGH AND LOW RISK MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF 57 PATIENTS TREATED WITH 4 DIFFERENT THERAPEUTIC REGIMENS 217
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 217
Inhibition of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) is a novel therapeutic strategy in B- and T-Acute Lymphoblastic Leukemia (ALL). 214
Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations 213
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis 213
The Inactivation of the Tumor Suppressor Genes CDKN2A/ARF by Genomic Deletions Frequently Occurs and Worsens Prognosis In Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Patients 213
LOSS OF THE TUMOR SUPPRESSOR GENE CDKN2A/ARF IS FREQUENTLY DELETED BUT NOT MUTATED IN BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS 213
The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report 212
Clustering Adult ACUTE Lymphoblastic Leukemia (ALL) Philadelphia Negative (Ph-) By Whole Exome Sequencing (WES) Analysis 211
First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 210
Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents 209
Distinct pattern of alterations in tp53 mutated and wild type acute myeloid leukemia (AML) patients 209
Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities 209
Ultra-deep sequencing (uds) allows more sensitive detection of the D816V and other kit gene mutations in systemic mastocytosis 208
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 208
Identification of Two DNMT3A Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia 207
Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort 206
A new biomarker of response to 5-azacitidine therapy in MDS and AML patients: SIRPB1 206
Copy number variants signature in two patients with relapsed acute promyelocytic leukemia 205
At the time of diagnosis, Ph cells from both chronic phase chronic myeloid leukemia and acute lymphoblastic leukemia patients already harbour BCR-ABL kinase domain mutations 204
A germline polymorphism in the ANRIL (CDKN2BAS) locus is associated with susceptibility to Philadelphia-positive acute lymphoblastic leukemia (ALL) 204
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents 203
Patologic IL 17 Producing Helper T Cells In Acute Myeloid Leukemia Patients 203
Novel Genomic Patterns of Metabolic Remodeling in Acute Myeloid Leukemia 203
BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS 203
Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia. 202
Low-Dose Anti-T Lymphoglobulin as Prophylaxis for Graft-versus-Host Disease in Unrelated Donor Transplantations for Acute Leukemias and Myelodysplastic Syndromes. 202
ACTIVATION-INDUCED CYTIDINE DEAMINASE IS ABERRANTLY OVEREXPRESSED IN BCRABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA CELLS AND PROMOTES DNA-SINGLE STRAND BREAKS 200
IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. 200
Bromodomain Inhibition Is Effective Against Acute Myeloid Leukemia Cells Under Hypoxia and Induces Genome-Dependent Metabolic Perturbations 200
BCR-ABL1-Positive Acute Lymphoblastic Leukemia Patients Treated with Only TKI Vs Conventional Chemo Plus TKI Therapy Show Similar DNA Alterations At Relapse Targeting Key Regulators of Tumor Suppression, Cell Cycle Control, and Lymphoid/B-Cell Development 200
BCR-ABL1 transcript detection in patients with Philadelphia-positive Acute Lymphoblastic Leukemia (ALL) using a new and high sensitive nanofluidic method 199
Donor Natural Killer (NK) Alloreactivity Predicts Long-Term Relapse-Free Survival in Acute Myeloid Leukemia Patients Undergoing Immunotherapy with NK Cells 199
Ultra-Deep Sequencing (UDS) Allows More Sensitive Detection of the D816V and Other Kit Gene Mutations in Systemic Mastocytosis 198
INO‐CD22: A multicenter, real‐world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia 196
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia 196
Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis 196
The Bcr-Abl kinase promotes aberrant expression of spliced oncogenic Ikaros isoforms in Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with tyrosine kinase inhibitors 195
Microarray analysis to identifiy novel copy number alterations in acute myeloid leukemia 195
Ex-Vivo Drug Response Profiling for Precision Medicine Approaches in Acute Myeloid Leukemia with the Open Microwell Microfluidic Platform 194
Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis 192
Totale 23.948
Salva come PNG Salva come JPEG
Categoria #
all - tutte 159.149
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 159.149
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.216 0 0 0 0 0 0 0 0 0 0 0 2.216
2021/20226.614 650 151 413 592 663 438 133 425 345 463 1.167 1.174
2022/20237.108 820 1.089 362 913 532 519 249 400 1.148 159 554 363
2023/20242.002 94 296 109 184 133 422 120 142 119 129 134 120
2024/20258.374 325 1.249 662 538 1.146 392 746 271 113 757 482 1.693
2025/202621.780 1.810 2.536 1.709 1.414 2.061 1.098 1.937 947 4.595 1.857 1.056 760
Totale 61.958